The standard treatment for hepatitis C virus (HCV) is poorly tolerated and ineffective in a large subset of HCV patients. Scientists at Stanford and UCSF have developed new therapeutic leads for HCV that also have potential to be broad-spectrum anti-infectives.
FragFEATURE is a data-driven computational method for fragment binding prediction. It predicts small molecule fragments preferred by a protein structure using a knowledge base of all previously observed protein-fragment interactions.
Druggability of a protein is its potential to be modulated by drug-like molecules. It is important in the target selection phase. We developed DrugFEATURE to quantify druggability by assessing the microenvironments in potential small-molecule binding sites.
Stanford and Rockefeller researchers have identified and developed dynein-specific inhibitors that have significant medical applications involving mitotic spindle assembly, organelle transport, and primary cilia formation.